Nuvo Research Announces Collaboration to Develop Topical Dermatology Products
News Apr 26, 2014
Nuvo Research Inc. has announced a collaboration involving Ferndale Laboratories, Inc. (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE™) technology.
"This exciting opportunity demonstrates how Nuvo can leverage one of our four proprietary technologies that enhances the delivery of active drugs into or through the skin," said Dan Chicoine, Nuvo's Chairman and Co-CEO. "This agreement validates our patented drug delivery platforms and highlights our ability to expand our development product pipeline through strategic collaborations with partners who will fund the costs of clinical development."
Under the terms of the collaboration agreement, Nuvo will utilize its proprietary MMPE technology to formulate two patented topical dermatology product candidates.
Once the formulations are complete, Ferndale in collaboration with the CRO, will oversee and fund the formulations' advancement through Phase 2 clinical studies. It is anticipated that the product candidates will then be made available for out-licensing.
Licensing revenues, including upfront payments, milestone payments and royalties will be shared by the parties based on a formula that includes compensation to Nuvo for contributing the patented formulations.
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE